Print this page    •   Back to Web version of article

Covalent Vaccination and Catalytic Antibodies: A New Way of Looking at an HIV Vaccine

By Sudhir Paul,*† Stephanie A. Planque,* Yasuhiro Nishiyama,* Miguel Escobar,* Zachary Barnett‡ and Richard J. Massey†

June 2011

Introduction

There is global concern regarding HIV drug-resistance, drug toxicity, and increasing drug costs. Many health care professionals believe that eradicating HIV will require development of a vaccine that prevents infection by the virus. Yet, one by one, classical vaccine approaches used for combating other infections have proved ineffective for HIV in clinical trials.

Nearly three decades of research has been invested in understanding how HIV overcomes immune defenses and why candidate HIV vaccines have been ineffective. Immune defense is provided by an ensemble of molecules and cells with innate and adaptive capability to counter infectious microbes. The innate immune capabilities have evolved over millions of years of evolution. Their functional importance resides in the immediate blockade of infection, for example, killing of microbes by macrophages that migrate to the infection site due to an inflammatory response. Vaccines generally work by inducing adaptive immunity developed over days to weeks. The functional mediators of adaptive immunity are antibodies and T lymphocytes that specifically recognize microbial antigens and help remove the microbe. HIV has developed various mechanisms to overcome natural immune defenses of humans. These mechanisms are also the reason for the failure of classical immunological approaches to yield an effective HIV vaccine.


Challenges Posed by HIV Immune Properties

Thousands of different HIV-1 strains have emerged. Most infections are initiated by strains that utilize chemokine coreceptor CCR5 for entry into host cells. Coreceptor CXCR4-dependent strains emerge with time. Both types of strains use CD4 as the primary host receptor to infect T cells and macrophages. Different parts of the world are dominated by strains belonging to different HIV-1 subtypes.1 Subtype C strains are found primarily in the developing world and account for a majority of infections globally.

A central problem is that most exposed components of HIV mutate rapidly, generating structural variations of the viral coat proteins. The mutable coat regions are also its dominant antigenic regions, also known as epitopes, against which the immune system produces antibodies and T lymphocytes.2 The original infecting strain induces a robust immune response, but new quasi-strains develop over the course of infection, and protection against the virus is transient at best. Similarly, the antigenic constituents incorporated in previously-tested candidate vaccines were drawn from a single HIV strain or at most a few strains. The candidate vaccines induced antibody responses and T cell responses mostly directed to the mutable coat protein regions, compromising their efficacy against structurally divergent virus strains in different individuals and in different parts of the world.

Advertisement

Over the course of the humoral immune response, antibody complementarity determining regions (CDRs) undergo rapid mutations under the selective pressure of antigen binding. This process generally generates neutralizing antibodies capable of high affinity antigen binding. One of the few immune vulnerabilities of HIV is the maintenance of its exposed CD4 binding site (CD4BS) on the surface of the coat protein gp120 in mostly constant form. The CD4BS is essential for virus-host cell binding and infection. Despite minimal chemical variability of the CD4BS, the immune system fails to mount a sufficiently protective antibody response to the CD4BS.

The reasons are complex. First, individual epitopes within the CD4BS are conformationally plastic, that is, the three-dimensional epitope structure can change during the process of infection. Initial CD4 binding at the CD4BS region located in the outer gp120 domain (CD4BSod) may induce a conformational change of the CD4BS core region composed of amino acids 421-433 (CD4BScore) that is essential for stable HIV-host cell binding. Consequently, the CD4BScore might exist in a conformation vulnerable to immune attack only transiently during the process of CD4BS-CD4 binding. Second, HIV utilizes an unusual evolutionary trick to preclude production of a protective antibody response by B lymphocytes. The CD4BScore expresses superantigen character.3,4 Superantigens bind specifically to innately-produced antibodies expressed on the surface of B lymphocytes, the B cell receptors. Unlike the stimulatory binding of traditional antigens to the B cell receptor, superantigen binding occurs at the antibody framework regions, and the functional consequence is down-regulation of B cell differentiation, premature cell death and failure to mount an adaptive antibody response. We suggested that the innate superantigen recognition capability of antibodies was originally developed by Darwinian evolution processes over millions of years as a defense against primordial microbes.5 HIV appears to have evolved a CD4BS with superantigenic character as the means to preclude an adaptive antibody response.


Novel Vaccine Approaches

Induction of neutralizing antibodies is the cornerstone of effective vaccination. Following failure of candidate protein and polypeptide vaccines to induce sufficient neutralizing antibodies to the free virus,6 the focus shifted to developing candidate DNA vaccines that induce cytotoxic T cells directed to HIV infected cells.7 This approach was also ineffective. The RV144 vaccine composed of full-length gp120 protein and a canary pox vector expressing the gp120/gag/protease genes reduced the risk of infection by 31%.8 It is unclear whether this is a statistically or clinically meaningful effect. Many in the field of HIV vaccine development believe that combined induction of neutralizing antibody and cytotoxic T cells is the favored approach. As the individual antibody and cytotoxic T cell responses to the mutable HIV regions are ineffective, it is not clear how combining these responses can be the basis for effective vaccination. Our view is that HIV vaccination will be feasible once an immunogen is identified that induces a sufficient immune response to a structurally constant region of HIV essential for virus infection and propagation.

The coat protein gp41 expresses certain structurally conserved regions. The vaccine approach of Barton Haynes at Duke University entails an epitope of the HIV gp41 coat protein located in the proximity of the lipid membrane.9 Polyspecific antibodies that recognize this epitope in conjunction with membrane lipids neutralize genetically divergent HIV strains. Membranes of uninfected cells also contain the lipids as self-antigens. The immune system is generally tolerant to the self-antigens, and anti-HIV antibodies that react with self-antigens can exert deleterious effects on the host. Nonetheless, there is strong interest in the notion that breaking tolerance to self-antigens may guide development of an immunogen capable of inducing HIV neutralizing antibodies.

Concerning the epitopes of the CD4BS, there is no evidence for insufficient physical exposure as the cause of insufficient antibody production. Similarly, an intrinsic defect in the CDR adaptive mutational process is theoretically possible, but there is no evidence that this is the reason for insufficient anti-CD4BS antibody production following HIV infection or administration of the previously-tested vaccine candidates. Burton and coworkers have identified rare antibodies that recognize a segment of the CD4BS (the CD4BSod) and neutralize genetically divergent HIV strains comparatively broadly.10 Reverse-engineering of peptides with structure complementary to the neutralizing antibody binding site can be conceived as a route to a vaccine that induces the synthesis of similar neutralizing antibodies upon administration to humans. A peptide immunogen designed using as template a neutralizing antibody to a segment of the CD4BS did not induce broadly neutralizing antibodies.11 Targeting a larger CD4BS surface area by a reverse-engineered immunogen could be more fruitful.

Our studies have identified the CD4BScore as the proverbial Achilles heel of the virus. In the rare circumstances that anti-CD4BScore antibodies are produced, they neutralize HIV strains from across the world with exceptional potency.12,13 Such antibodies were found in non-infected patients with lupus, an autoimmune disease that is rarely associated with concurrent HIV infection, and in long-term survivors of HIV infection. It appears that HIV is highly vulnerable to neutralization by specific antibodies to the CD4BScore region, but the adaptive immune response to the region is insufficient to control infection under normal circumstances. A clear path to an HIV vaccine that induces broadly neutralizing antibodies can be foreseen if the following milestones can be reached: a) Reproduction of the correct CD4BScore conformation in the vaccine candidate, and b) Rapid adaptive production of neutralizing anti-CD4BScore antibodies upon administration of the vaccine candidate.

Our preclinical studies in experimental animals based on the covalent vaccination strategy suggest the feasibility of attaining the foregoing milestones.14,15 Central points in the strategy are:

Taken together, our studies indicate the feasibility of developing an HIV vaccine capable of directing the innate CD4BS recognition capability of B cells towards a favorable maturational pathway, eventually resulting in synthesis of broadly neutralizing antibodies.


Catalytic Antibodies (Abzymes)

Reversible CD4BS binding by antibodies alone is sufficient to neutralize HIV. A subset of antibodies produced by B cells express the ability to catalyze the breakdown of peptide bonds, destroying gp120 permanently.19 A single catalytic antibody molecule is reused to cleave thousands of gp120 molecules over its biological half-life in blood (1-3 weeks). The neutralization potency of catalytic antibodies, therefore, is superior to traditional antibodies that bind the antigen reversibly on a 1:1 basis. Antibody catalytic sites belong to the serine protease enzyme family, consisting of nucleophilic sites similar to the archetypical Serine-Histidine-Aspartate catalytic triad of trypsin. Catalysis occurs by formation of a covalent intermediate and water attack on the intermediate, regenerating an antibody molecule that is reused for additional catalytic cycles.

Catalytic cleavage of gp120 occurs by noncovalent CD4BScore binding followed by cleavage of peptide bonds. The catalytic sites are present in antibodies produced without exposure to HIV.20,21 Sexual transmission of HIV generally occurs through the rectal and vaginal mucosal surfaces. Only a minority of sexual intercourse events with an infected individual results in transmission of the virus. Secretory IgA class antibodies found at mucosal surfaces of non-infected humans catalyze rapid gp120 cleavage and neutralize HIV in tissue culture.22 It may be hypothesized that the catalytic IgAs constitute a natural defense against mucosal HIV transmission.

In addition to inducing reversibly-binding antibodies, the covalent vaccination approach described in the preceding section stimulates adaptive improvement of the nucleophilic function of antibodies. This is feasible because covalent binding of the electrophilic vaccine candidate selects B cell receptors with the greatest nucleophilic reactivity.23,24 In turn, the improved nucleophilic reactivity enhances antibody inactivation of HIV as follows. First, specific pairing of the antibody nucleophile with the weakly electrophilic carbonyls of gp120 forms stable immune complexes with covalent character. Covalently binding antibodies were induced by immunization with the electrophilic analogs of full-length gp120 and a synthetic gp120 peptide. Reversibly bound antibodies dissociate from HIV readily. As the covalent bond is very strong, the covalent antibody-HIV complexes do not dissociate, increasing the HIV neutralization potency. Second, if the antibody combining site supports water attack on the covalent gp120-antibody complex, catalytic gp120 cleavage occurs. A subset of antibodies obtained by immunization with the electrophilic CD4BScore peptide catalyzed the cleavage of gp120 rapidly.

Treatment of HIV using reverse transcriptase and protease inhibitors requires vigilant management because of the potential for toxicity and emergence of drug-resistant strains. This has generated interest in passive immunotherapy using monoclonal antibodies. Control of viremia upon infusion of reversibly binding anti-HIV antibodies in humans was transient, suggesting emergence of antibody-resistant viral mutants. Very large quantities of the antibodies were necessary to reduce viral load, a reflection of modest antibody neutralizing potency. Can catalytic antibodies be used for passive immunotherapy of HIV infection? The answer depends on the epitope specificity and neutralizing potency of the catalysts. Targeting the CD4BScore minimizes the opportunity for development of antibody resistant strains, as CD4 binding and mutations in the CD4BScore are predicted to result in loss of CD4 binding activity. Indeed, anti-CD4BScore antibodies from long-term survivors of HIV infection neutralized the autologous HIV strain potently. There is no evidence, therefore, for emergence of resistant strains despite the selective pressure imposed by the anti-CD4BScore antibodies over prolonged durations. Anti-CD4BScore antibodies neutralize HIV in tissue culture with nanogram/ml potency, supporting their potential therapeutic application.

In addition to gp120, two additional HIV proteins essential for virus infection are cleaved by catalytic antibodies, reverse transcriptase and integrase.25,26

Intracellular expression of catalytic antibodies to these proteins holds potential for early blockade of viral propagation via interference with copying viral RNA into proviral DNA and DNA integration into the host genome. Gene therapy protocols for intracellular antibody expression27 can be conceived for persistent delivery of catalytic anti-HIV antibodies. Reactivation of HIV infection can occur due to integration of the viral genome into host DNA. Drugs that deplete proviral DNA reservoirs are under investigation to address the problem of HIV latency.28 Catalytic antibodies combined with a proviral DNA-depleting drug may be suitable for consideration as an alternative therapy for the infection.


Prioritization and Funding of New Technology Development

A prophylactic vaccine and a cure for patients infected with HIV are needed urgently. However, there is considerable pessimism because of repeated clinical failure of candidate vaccines. The seemingly insoluble nature of HIV has even inspired an argument for use of the limited available funding for improved delivery of available anti-retroviral drugs to infected patients rather than further research investment. This argument is misguided. Innovative preclinical approaches are essential if the objective of eradicating HIV infection is to be met. Our positive preclinical studies using the covalent vaccination and catalytic antibody approaches are an example. These approaches were developed under basic immunology grants funded by the National Institute of Health over the past two decades. Additional developmental efforts will be necessary to obtain a standardized covalent vaccine and catalytic antibody candidates for human trials, but there is hope for translation of the preclinical immunological advances into clinical success.

In the U.S., elaborate governmental arrangements are in place to prioritize the competing developmental approaches for funding, including excellent scientific peer-review arrangements. However, programmatic allocation of funds is inspired at least in part by non-scientific reasons. The literature is replete with claims of potential clinical advances. On the other hand, most HIV vaccine development projects are likely to yield incremental advances at best. An example is the continued testing of vaccine formulations that induce immune responses primarily to mutable regions of HIV. Likewise, intensive efforts have been undertaken to identify immune markers correlating with the marginal risk reduction observed in the RV144 vaccine trial. As there is doubt whether the vaccine candidate really reduced the risk of infection, it is hard to accept that meaningful correlates of risk reduction will emerge. A policy change that forthrightly admits the limited utility of classical vaccine approaches and explicitly encourages credible, novel approaches would be a welcome event.

Scientific approaches that diverge radically from established paradigms are invariably subject to rigorous peer evaluation. Independent reproduction of the evidence is usually necessary prior to widespread acceptance of the new scientific approach. These are essential safeguards against mistaken conclusions and spurious claims. Antibodies obtained by the covalent vaccine approach have been independently verified to neutralize diverse HIV strains in tissue culture. Factors that might result in artifactual neutralization have been carefully eliminated.29,30 Similarly, the chemical and immunological principles underlying antibody catalysis have been amply validated by researchers across the world. Occam's razor is yet another safeguard against unproductive science -- when confronted with alternative explanations that are equal in other respects, the hypothesis that makes the fewest novel assumptions should be selected for further study. It is necessary to invoke B cell superantigenicity as the cause of poor CD4BS immunogenicity, as no competing hypothesis explains the empirical findings adequately. Similarly, the innovation of covalent bonding of the vaccine candidate to B cells is necessary, as no alternative strategy is available to induce a robust anti-CD4BS antibody response. In summary, the preclinical scientific findings support translation research aimed at realizing the clinical utility of the technology.


Conclusion

Recent immunogenicity and virus neutralization data encourages the belief that it may be possible to develop a covalent HIV vaccine that induces broadly neutralizing antibodies directed at the CD4 binding site of the virus. Catalytic antibodies to HIV appear to be a natural defense mechanism against HIV, and it may be possible to apply broadly neutralizing catalytic antibodies as an alternative therapy for HIV infection.

Acknowledgments

The authors' research was funded by the National Institutes of Health, University of Texas Houston Medical School, Abzyme Research Foundation and Covalent Bioscience Inc. We thank Dr. Carl Hanson for reading the manuscript and discussions.


Conflict Statement

Sudhir Paul, Stephanie Planque, Miguel Escobar and Yasuhiro Nishiyama have a financial interest in patents covering the covalent immunization and catalytic antibody areas. Sudhir Paul and Richard Massey have a financial interest in Covalent Bioscience Inc. Sudhir Paul is scientific advisor for the company.


Affiliation

* Chemical Immunology Research Center and Gulf States Hemophilia and Thrombophilia Center, Departments of Pathology and Pediatrics, University of Texas-Houston Medical School; † Covalent Bioscience Inc; ‡ Abzyme Research Foundation


References

  1. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med 2008,358:1590-1602.
  2. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 2008,6:143-155.
  3. Goodglick L, Zevit N, Neshat MS, Braun J. Mapping the Ig superantigen-binding site of HIV-1 gp120. J Immunol 1995,155:5151-5159.
  4. Berberian L, Goodglick L, Kipps TJ, Braun J. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science 1993,261:1588-1591.
  5. Planque S, Nishiyama Y, Taguchi H, Salas M, Hanson C, Paul S. Catalytic antibodies to HIV: physiological role and potential clinical utility. Autoimmun Rev 2008,7:473-479.
  6. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006,194:1661-1671.
  7. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008,205:7-12.
  8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009,361:2209-2220.
  9. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005,308:1906-1908.
  10. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007,445:732-737.
  11. Saphire EO, Montero M, Menendez A, van Houten NE, Irving MB, Pantophlet R, et al. Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. J Mol Biol 2007,369:696-709.
  12. Karle S, Planque S, Nishiyama Y, Taguchi H, Zhou YX, Salas M, et al. Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library. AIDS 2004,18:329-331.
  13. Planque S, Salas M, Mitsuda Y, Sienczyk M, Escobar MA, Mooney JP, et al. Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. AIDS 2010,24:875-884.
  14. Nishiyama Y, Planque S, Mitsuda Y, Nitti G, Taguchi H, Jin L, et al. Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity. J Biol Chem 2009,284:30627-30642.
  15. Planque S, Mitsuda, Y, Ghosh, D, Nishiyama, Y, Hanson, C.V, Paul, S, 18-23 August, 2010, Vienna, Austria; Prototype covalent HIV vaccine for inducing antibodies that neutralize genetically divergent virus strains. XVIII International AIDS Conference 2010, Abstract: TUAA0101. Slide presentation available at http://pag.aids2010.org/flash/?pid=100572.
  16. Planque S, Taguchi H, Burr G, Bhatia G, Karle S, Zhou YX, et al. Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity. J Biol Chem 2003,278:20436-20443.
  17. Nishiyama Y, Planque S, Mitsuda Y, Nitti G, Taguchi H, Jin L, et al. Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity. J Biol Chem 2009,284:30627-30642.
  18. Planque S, Mitsuda, Y, Ghosh, D, Nishiyama, Y, Hanson, C.V, Paul, S, 18-23 August, 2010, Vienna, Austria; Prototype covalent HIV vaccine for inducing antibodies that neutralize genetically divergent virus strains. XVIII International AIDS Conference 2010, Abstract: TUAA0101. Slide presentation available at http://pag.aids2010.org/flash/?pid=100572.
  19. Paul S, Karle S, Planque S, Taguchi H, Salas M, Nishiyama Y, et al. Naturally occurring proteolytic antibodies: selective immunoglobulin M-catalyzed hydrolysis of HIV gp120. J Biol Chem 2004,279:39611-39619.
  20. Ibid.
  21. Planque S, Mitsuda Y, Taguchi H, Salas M, Morris MK, Nishiyama Y, et al. Characterization of gp120 Hydrolysis by IgA Antibodies from Humans without HIV Infection. AIDS Res Hum Retroviruses 2007,23:1541-1554.
  22. Ibid.
  23. Paul S, Planque S, Zhou YX, Taguchi H, Bhatia G, Karle S, et al. Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J Biol Chem 2003,278:20429-20435.
  24. Nishiyama Y, Mitsuda Y, Taguchi H, Planque S, Salas M, Hanson CV, Paul S. Towards covalent vaccination: improved polyclonal HIV neutralizing antibody response induced by an electrophilic gp120 V3 peptide analog. J Biol Chem 2007,282:31250-31256.
  25. Odintsova ES, Kharitonova MA, Baranovskii AG, Sizyakina LP, Buneva VN, Nevinsky GA. Proteolytic activity of IgG antibodies from blood of acquired immunodeficiency syndrome patients. Biochemistry (Mosc) 2006,71:251-261.
  26. Baranova SV, Buneva VN, Kharitonova MA, Sizyakina LP, Calmels C, Andreola ML, et al. HIV-1 integrase-hydrolyzing IgM antibodies from sera of HIV-infected patients. Int Immunol 2010,22:671-680.
  27. Vercruysse T, Pardon E, Vanstreels E, Steyaert J, Daelemans D. An intrabody based on a llama single-domain antibody targeting the N-terminal alpha-helical multimerization domain of HIV-1 rev prevents viral production. J Biol Chem 2010,285:21768-21780.
  28. Savarino A, Mai A, Norelli S, El Daker S, Valente S, Rotili D, et al. "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 2009,6:52.
  29. Planque S, Salas M, Mitsuda Y, Sienczyk M, Escobar MA, Mooney JP, et al. Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. AIDS 2010,24:875-884.
  30. Nishiyama Y, Planque S, Mitsuda Y, Nitti G, Taguchi H, Jin L, et al. Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity. J Biol Chem 2009,284:30627-30642.




This article was provided by Gay Men's Health Crisis. It is a part of the publication GMHC Treatment Issues. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/65297/covalent-vaccination-and-catalytic-antibodies-a-ne.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.